Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Smoldering Multiple Myeloma × elotuzumab × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 23 Recurrence 4 Neoplasms, Plasma Cell 2 Smoldering Multiple Myeloma 1 Neoplasms 1 Lymphoma 1 Leukemia, Myeloid, Acute 1

Interventions

daratumumab 2 siltuximab 1 sargramostim 1 elotuzumab 1 PVX-410 vaccine 1 Monatide (IMS 3015) 1 Lenalidomide 1 IPH-2101 1 Emulsions 1 BHQ880 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01441973 2018-01-23

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Bristol-Myers Squibb

Phase 2 Completed

41 enrolled 17 charts

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡